Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:EMBI NASDAQ:NAUT NASDAQ:QIPT NASDAQ:ZURA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEMBIEmerald Bioscience$0.00$0.02▼$0.20$24.13M0.4314.24 million shs6.96 million shsNAUTNautilus Biotechnology$0.76+0.6%$0.75$0.66▼$3.09$96.42M1.42163,051 shs139,938 shsQIPTQuipt Home Medical$2.31+4.5%$1.96$1.35▼$3.75$100.35M0.59275,320 shs270,035 shsZURAZura Bio$1.50+7.1%$1.28$0.97▼$5.07$102.56M-0.06990,155 shs471,118 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEMBIEmerald Bioscience0.00%0.00%0.00%0.00%0.00%NAUTNautilus Biotechnology0.00%+0.84%-7.02%+11.54%-68.42%QIPTQuipt Home Medical0.00%+3.59%+29.78%+7.44%-38.24%ZURAZura Bio0.00%-8.54%+32.04%+4.17%-58.79%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEMBIEmerald BioscienceN/AN/AN/AN/AN/AN/AN/AN/ANAUTNautilus Biotechnology3.3016 of 5 stars2.55.00.00.03.44.20.6QIPTQuipt Home Medical2.0154 of 5 stars2.35.00.00.01.91.70.6ZURAZura Bio3.6187 of 5 stars3.65.00.00.03.42.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEMBIEmerald Bioscience 0.00N/AN/AN/ANAUTNautilus Biotechnology 1.00Sell$2.13178.03% UpsideQIPTQuipt Home Medical 2.50Moderate Buy$2.8523.38% UpsideZURAZura Bio 3.13Buy$14.33855.56% UpsideCurrent Analyst Ratings BreakdownLatest EMBI, QIPT, NAUT, and ZURA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025QIPTQuipt Home MedicalBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $4.005/13/2025QIPTQuipt Home MedicalCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$4.00 ➝ $1.705/9/2025ZURAZura BioOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$19.00 ➝ $17.00(Data available from 8/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEMBIEmerald BioscienceN/AN/AN/A1.20N/AN/ANAUTNautilus BiotechnologyN/AN/AN/AN/A$1.66 per shareN/AQIPTQuipt Home Medical$245.91M0.41$1.02 per share2.27$2.49 per share0.93ZURAZura BioN/AN/AN/AN/A$2.27 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEMBIEmerald Bioscience$1.05M-$0.08N/AN/AN/AN/AN/A-347.62%N/ANAUTNautilus Biotechnology-$70.78M-$0.52N/AN/AN/AN/A-32.53%-27.85%N/AQIPTQuipt Home Medical-$6.76M-$0.21N/AN/AN/A-3.66%-8.38%-3.63%8/11/2025 (Estimated)ZURAZura Bio-$45.39M-$0.70N/AN/AN/AN/A-42.84%-35.22%8/12/2025 (Estimated)Latest EMBI, QIPT, NAUT, and ZURA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025ZURAZura Bio-$0.19N/AN/AN/AN/AN/A8/11/2025Q3 2025QIPTQuipt Home Medical$0.03N/AN/AN/A$80.37 millionN/A7/31/2025Q2 2025NAUTNautilus Biotechnology-$0.14-$0.12+$0.02-$0.12N/AN/A5/12/2025Q2 2025QIPTQuipt Home Medical$0.02-$0.07-$0.09-$0.07$88.29 million$57.40 million5/8/2025Q1 2025ZURAZura Bio-$0.17-$0.19-$0.02-$0.19N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEMBIEmerald BioscienceN/AN/AN/AN/AN/ANAUTNautilus BiotechnologyN/AN/AN/AN/AN/AQIPTQuipt Home MedicalN/AN/AN/AN/AN/AZURAZura BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEMBIEmerald Bioscience0.433.593.59NAUTNautilus BiotechnologyN/A18.5218.52QIPTQuipt Home Medical0.761.220.85ZURAZura BioN/A8.148.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEMBIEmerald Bioscience5.58%NAUTNautilus Biotechnology50.71%QIPTQuipt Home Medical42.85%ZURAZura Bio61.14%Insider OwnershipCompanyInsider OwnershipEMBIEmerald Bioscience1.60%NAUTNautilus Biotechnology41.10%QIPTQuipt Home Medical13.40%ZURAZura Bio14.23%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEMBIEmerald Bioscience4268.07 millionN/ANot OptionableNAUTNautilus Biotechnology130126.15 million74.30 millionOptionableQIPTQuipt Home Medical1,20043.44 million37.62 millionOptionableZURAZura Bio368.38 million53.26 millionOptionableEMBI, QIPT, NAUT, and ZURA HeadlinesRecent News About These CompaniesRobert Lisicki on Living Up to Zura Bio’s Heroic NamesakeJuly 31, 2025 | pharmexec.comP3 Penny Stocks With Market Caps Over $70M Worth WatchingJuly 18, 2025 | finance.yahoo.comZura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 18, 2025 | finance.yahoo.comZura Bio Limited (NASDAQ:ZURA) Given Consensus Recommendation of "Buy" by AnalystsJuly 13, 2025 | marketbeat.comZura Bio (NASDAQ:ZURA) Trading 12.5% Higher - Here's What HappenedJuly 10, 2025 | marketbeat.comZura Bio Announces Chief Financial Officer TransitionJuly 1, 2025 | businesswire.comZura Bio shareholders approve board nominees and auditorMay 24, 2025 | investing.comZura Bio commences Phase II trial of tibulizumab for hidradenitis suppurativaMay 21, 2025 | msn.comZura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis SuppurativaMay 20, 2025 | businesswire.comZura Bio Reports First Quarter 2025 Financial Results and Recent Corporate UpdatesMay 9, 2025 | standard-journal.comSAfter losing 56% in the past year, Zura Bio Limited (NASDAQ:ZURA) institutional owners must be relieved by the recent gainApril 24, 2025 | finance.yahoo.comZura Bio price target lowered to $3 from $5 at H.C. WainwrightApril 4, 2025 | markets.businessinsider.comZura Bio (ZURA) Gets a Buy from GuggenheimMarch 31, 2025 | markets.businessinsider.comHopeful Week For Insiders Who Bought US$1.01m Of Zura Bio StockMarch 26, 2025 | finance.yahoo.comZura Bio Limited: 2024 Financial Results and Strategic ProgressMarch 25, 2025 | tipranks.comZura Bio Reports Full Year 2024 Financial Results and Recent Corporate UpdatesMarch 25, 2025 | businesswire.comZura Bio to Present at the Leerink Partners Global Healthcare ConferenceFebruary 24, 2025 | businesswire.comZURA stock touches 52-week low at $1.44 amid market shiftsFebruary 11, 2025 | msn.comDown -35.58% in 4 Weeks, Here's Why You Should You Buy the Dip in Zura Bio Limited (ZURA)January 24, 2025 | zacks.comWe Think Zura Bio (NASDAQ:ZURA) Can Afford To Drive Business GrowthJanuary 22, 2025 | finance.yahoo.comZura Bio Highlights Strategic Goals and Clinical AdvancesJanuary 13, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEMBI, QIPT, NAUT, and ZURA Company DescriptionsEmerald Bioscience OTCMKTS:EMBIEmerald Bioscience, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics for unmet medical needs worldwide. The company's lead product candidate is NB1111, which is in preclinical trials for the treatment of glaucoma. It is also developing NB2222, a product candidate in preclinical trials for use in the treatment of various eye diseases, including uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy; and NB3111, a cannabinoid cocktail in testing for use as an anti-infective agent against various strains of antibiotic resistant bacteria, including methicillin-resistant Staphylococcus aureus. The company was formerly known as Nemus Bioscience, Inc. and changed its name to Emerald Bioscience, Inc. in March 2019. Emerald Bioscience, Inc. was founded in 2012 and is based in San Diego, California.Nautilus Biotechnology NASDAQ:NAUT$0.76 +0.00 (+0.57%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.76 +0.00 (+0.09%) As of 08/1/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Quipt Home Medical NASDAQ:QIPT$2.31 +0.10 (+4.52%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.46 +0.15 (+6.49%) As of 04:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Quipt Home Medical Corp., through its subsidiaries, engages in the provision of durable and home medical equipment and supplies in the United States. The company offers nebulizers, oxygen concentrators, and CPAP and BiPAP units; traditional and non-traditional durable medical respiratory equipment and services; non-invasive ventilation equipment, supplies, and services; and engages in the rental of medical equipment. It offers management of various chronic disease states focusing on patients with heart and pulmonary disease, sleep apnea, reduced mobility, and other chronic health conditions. The company was formerly known as Protech Home Medical Corp. and changed its name to Quipt Home Medical Corp. in May 2021. Quipt Home Medical Corp. is headquartered in Wilder, Kentucky.Zura Bio NASDAQ:ZURA$1.50 +0.10 (+7.14%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.58 +0.08 (+5.00%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
